Publisher Correction: A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity

Yang, Jingyun; Wang, Wei; Chen, Zimin; Lu, Shuaiyao; Yang, Fulun; Bi, Zhenfei; Bao, Linlin; Mo, Fei; Li, Xue; Huang, Yong; Hong, Weiqi; Yang, Yun; Zhao, Yuan; Ye, Fei; Lin, Sheng; Deng, Wei; Chen, Hua; Hong, Lei; Zhang, Ziqi; Luo, Min; Gao, Hong; Zheng, Yue; Gong, Yanqiu; Jiang, Xiaohua; Xu, Yanfeng; Lv, Qi; Li, Dan; Wang, Manni; Li, Fengdi; Wang, Shunyi; Wang, Guanpeng; Yü, Ping; Qu, Yajin; Yang, Li; Deng, Hongxin; Tong, Aiping; Li, Jiong; Wang, Zhenling; Yang, Jinliang; Shen, Guobo; Zhao, Zhiwei; Li, Yuhua; Luo, Jingwen; Liu, Hongqi; Wu, Yu; Yang, Mengli; Xu, Jingwen; Wang, Junbin; Li, Haiyan; Wang, Haixuan; Kuang, Dexuan; Lin, Panpan; Hu, Zhengtao; Guo, Wei; Cheng, Wei; He, Yanlin; Song, Xiangrong; Chen, Chong; Xue, Zhihong; Yao, Su; Chen, Lu; Ma, Xuelei; Chen, Siyuan; Gou, Maling; Huang, Weijin; Wang, Youchun; Fan, Chen; Tian, Zhixin; Shi, Ming; Wang, Fu Sheng; Dai, Lunzhi; Wu, Min; Li, Gen; Wang, Guangyu; Peng, Yong; Qian, Zhiyong; Huang, Canhua; Lau, Johnson Y. N.; Yang, Zhenglin; Wei, Yuquan; Cen, Xiaobo; Peng, Xiaozhong; Qin, Chuan; Zhang, Kang; Lu, Guangwen; Wei, Xiawei

doi:10.1038/s41586-020-03108-4

Cited by 8 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 34 ] found that the most severely COVID-19 patients experienced a cytokine storm (CS), characterized by the presence of higher levels of proinflammatory cytokines in the serum [ 35 ]. Therefore, the measurement of anti-S IgG levels can be a reliable and convenient tool for assessing the immunological response of COVID-19-infected individuals, to quantify the immunogenicity of vaccines and therapeutic efforts [ 36 , 37 ].…”

Section: Discussionmentioning

confidence: 99%

Long-term persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein-specific and neutralizing antibodies in recovered COVID-19 patients

et al. 2022

View full text Add to dashboard Cite

Understanding antibody responses after natural severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can guide the coronavirus disease 2019 (COVID-19) vaccine schedule, especially in resource-limited settings. This study aimed to assess the dynamics of SARS-CoV-2 antibodies, including anti-spike protein 1 (S1) immunoglobulin (Ig)G, anti-receptor-binding domain (RBD) total Ig, anti-S1 IgA, and neutralizing antibody against wild-type SARS-CoV-2 over time in a cohort of patients who were previously infected with the wild-type SARS-CoV-2. Between March and May 2020, 531 individuals with virologically confirmed cases of wild-type SARS-CoV-2 infection were enrolled in our immunological study. Blood samples were collected at 3-, 6-, 9-, and 12-months post symptom onset or detection of SARS-CoV-2 by RT-PCR (in asymptomatic individuals). The neutralizing titers against SARS-CoV-2 were detected in 95.2%, 86.7%, 85.0%, and 85.4% of recovered COVID-19 patients at 3, 6, 9, and 12 months after symptom onset, respectively. The seropositivity rate of anti-S1 IgG, anti-RBD total Ig, anti-S1 IgA, and neutralizing titers remained at 68.6%, 89.6%, 77.1%, and 85.4%, respectively, at 12 months after symptom onset. We observed a high level of correlation between neutralizing and SARS-CoV-2 spike protein-specific antibody titers. The half-life of neutralizing titers was estimated at 100.7 days (95% confidence interval = 44.5–327.4 days, R2 = 0.106). These results support that the decline in serum antibody levels over time in both participants with severe disease and mild disease were depended on the symptom severity, and the individuals with high IgG antibody titers experienced a significantly longer persistence of SARS-CoV-2-specific antibody responses than those with lower titers.

show abstract

Section: Discussionmentioning

confidence: 99%

Long-term persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein-specific and neutralizing antibodies in recovered COVID-19 patients

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The SARS-CoV-2 RBD has been a functional antigenic during the development of candidate vaccines for COVID-19 ( 31 ). However, undesired major immune responses have presented a great threat and largely limited its practical applications.…”

Section: Discussionmentioning

confidence: 99%

A Highly Conserved Peptide Vaccine Candidate Activates Both Humoral and Cellular Immunity Against SARS-CoV-2 Variant Strains

Gao

Huang

et al. 2021

Front. Immunol.

View full text Add to dashboard Cite

Facing the imminent need for vaccine candidates with cross-protection against globally circulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutants, we present a conserved antigenic peptide RBD9.1 with both T-cell and B-cell epitopes. RBD9.1 can be recognized by coronavirus disease 2019 (COVID-19) convalescent serum, particularly for those with high neutralizing potency. Immunization with RBD9.1 can successfully induce the production of the receptor-binding domain (RBD)-specific antibodies in Balb/c mice. Importantly, the immunized sera exhibit sustained neutralizing efficacy against multiple dominant SARS-CoV-2 variant strains, including B.1.617.2 that carries a point mutation (SL452R) within the sequence of RBD9.1. Specifically, SY451 and SY454 are identified as the key amino acids for the binding of the induced RBD-specific antibodies to RBD9.1. Furthermore, we have confirmed that the RBD9.1 antigenic peptide can induce a S448-456 (NYNYLYRLF)-specific CD8+ T-cell response. Both RBD9.1-specific B cells and the S448-456-specific T cells can still be activated more than 3 months post the last immunization. This study provides a potential vaccine candidate that can generate long-term protective efficacy over SARS-CoV-2 variants, with the unique functional mechanism of activating both humoral and cellular immunity.

show abstract

“…Meanwhile, Huang et al 29 found that the most severely COVID-19 patients experienced a cytokine storm (CS), characterized by the presence of higher levels of proin ammatory cytokines in the serum 30 . Therefore, the measurement of anti-S IgG levels can be a reliable and convenient tool for assessing the immunological response of COVID-19-infected individuals, to quantify the immunogenicity of vaccines and therapeutic efforts 31,32 .…”

Section: Discussionmentioning

confidence: 99%

Long-term persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein-specific and neutralizing antibodies in recovered COVID-19 patients

Chansaenroj

Yorsaeng

Wanlapakorn

et al. 2021

Preprint

View full text Add to dashboard Cite

Understanding antibody responses after natural severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can guide the coronavirus disease 2019 (COVID-19) vaccine schedule. This study aimed to assess the dynamics of SARS-CoV-2 antibodies, including anti-spike protein 1 (S1) immunoglobulin (Ig)G, anti-receptor-binding domain (RBD) total Ig, anti-S1 IgA, and neutralizing antibody against wild-type SARS-CoV-2 in a cohort of patients who were previously infected with SARS-CoV-2. Between March and May 2020, 531 individuals with virologically confirmed cases of SARS-CoV-2 infection were enrolled in our immunological study. The neutralizing titers against SARS-CoV-2 were detected in 95.2%, 86.7%, 85.0%, and 85.4% of recovered COVID-19 patients at 3, 6, 9, and 12 months after symptom onset, respectively. The seropositivity rate of anti-S1 IgG, anti-RBD total Ig, anti-S1 IgA, and neutralizing titers remained at 68.6%, 89.6%, 77.1%, and 85.4%, respectively, at 12 months after symptom onset. The half-life of neutralizing titers was estimated at 100.7 days (95% confidence interval = 44.5 – 327.4 days, R2 = 0.106). These results support that the decline in serum antibody levels over time depends on the symptom severity, and the individuals with high IgG antibody titers experienced a significantly longer persistence of SARS-CoV-2-specific antibody responses than those with lower titers.

show abstract

Publisher Correction: A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity

Cited by 8 publications

References 0 publications

Long-term persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein-specific and neutralizing antibodies in recovered COVID-19 patients

Long-term persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein-specific and neutralizing antibodies in recovered COVID-19 patients

A Highly Conserved Peptide Vaccine Candidate Activates Both Humoral and Cellular Immunity Against SARS-CoV-2 Variant Strains

Long-term persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein-specific and neutralizing antibodies in recovered COVID-19 patients

Contact Info

Product

Resources

About